Sidley advised R-Bridge II Investment One Limited, a subsidiary of healthcare-focused CBC Group, on a US$40 million royalty-linked pre-IPO financing for Mirxes Holding Company Limited (“Mirxes”), a Singapore-headquartered RNA technology company that is a pioneer and leader in developing and commercializing accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. This financing is innovative, and of strategic importance, as it provides an important source of funding at a critical stage of Mirxes’ growth cycle.
CBC is Asia's largest healthcare-dedicated asset management firm, focused on platform building, buyout, private credit, and real assets, across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services. CBC Group actively invests in, and empower, leading healthcare companies with a mission to widen access to affordable medical care, catalyse innovations, and improve efficiency in fulfilling unmet medical needs in Asia and beyond. CBC Group provides alternative, non-dilutive financing to healthcare companies backed by royalties, revenue interest, and other cash flows generated by the sale of healthcare products and services in Greater China, the first of its kind in the asset class and region.
The Sidley team was led by Olivia Ngan (partner, Hong Kong). Other major team members included Kelly Lam (managing associate, Hong Kong), Horine Ye (senior managing associate, Hong Kong), and Wilfred Ong (managing associate, Singapore). Raymond Oh (partner, Hong Kong/Singapore) and Ryan Lim (managing associate, Singapore) provided support on project due diligence.
Sidley has been ranked as “Leading International Firm in Banking & Finance” by Chambers Greater China Region 2024-2025, “Leading Firm: Banking and Finance in Hong Kong” by The Legal 500 Asia Pacific 2023-2025, and “Firm of the Year: Banking and Finance” at the China Business Law Awards 2023. The team has received a number of accolades by independent organizations including The Asset and IFLR Asia-Pacific Awards.
Sidley’s China Life Sciences practice is an integrated part of the firm’s Global Life Sciences practice, which has more than 200 dedicated lawyers worldwide. It is the only Band One firm ranked by Chambers Greater China Region/APAC in life sciences for 16 consecutive years. Sidley advises clients along the full business lifecycle, from company formation, corporate governance (including incentive plans), and compliance operations for the startup phase; to product collaboration, licensing, commercialization, and regulatory filing matters in the business development phase; to initial public offerings, refinancings, and debt issuances in the capital-raising phase; to further significant transactions including domestic and cross-border mergers and acquisitions, asset restructurings, and privatizations, as well as dispute resolution.
